Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells

Since the start of the COVID-19 outbreak, pharmaceutical companies and research groups have focused on the development of vaccines and antiviral drugs against SARS-CoV-2. Here, we apply a drug repurposing strategy to identify drug candidates that are able to block the entrance of the virus into huma...

Descripción completa

Detalles Bibliográficos
Autores principales: Peralta-Garcia, Alejandro, Torrens-Fontanals, Mariona, Stepniewski, Tomasz Maciej, Grau-Expósito, Judith, Perea, David, Ayinampudi, Vikram, Waldhoer, Maria, Zimmermann, Mirjam, Buzón, María J., Genescà, Meritxell, Selent, Jana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707862/
https://www.ncbi.nlm.nih.gov/pubmed/34948390
http://dx.doi.org/10.3390/ijms222413592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707862/
https://www.ncbi.nlm.nih.gov/pubmed/34948390
http://dx.doi.org/10.3390/ijms222413592

Ejemplares similares